TC
ALNY icon

Telemus Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Telemus Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,000
Closed -$436K – 378
2020
Q3 		$436K Hold
3,000
– – 0.03% 327
2020
Q2 		$487K Hold
3,000
– – 0.04% 279
2020
Q1 		$406K Buy
+3,000
New +$346K 0.03% 275

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Telemus Capital's ALNY Position: Q4 2020 in Review

Telemus Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2020, closing a stake of 3,000 shares — an estimated $436K sold.

Telemus Capital first reported a position in ALNY in Q1 2020 and held it in 3 quarters. The position peaked at $487K in Q2 2020. 376 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

  • Telemus Capital reported no remaining Alnylam Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Telemus Capital sold 3,000 Alnylam Pharmaceuticals shares in Q4 2020, an estimated $436K.
  • Telemus Capital first reported a position in Alnylam Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • Telemus Capital's Alnylam Pharmaceuticals position peaked at $487K in Q2 2020.
  • 376 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on Telemus Capital's 13F filing for Q4 2020, filed 28 Jan 2021.